What question did this study set out to answer?

The aim is to compare lipoprotein(a) levels in patients with coronary artery disease and healthy individuals.

February 8, 2026

Comparison of lipoprotein (a) levels in patients with a history of coronary artery disease and in normal subjects

TOT OkadaKagawa Prefectural Central Hospital TMT MiyoshiOkayama University STS TsujiKagawa Prefectural Central Hospital

Key Points

The aim is to compare lipoprotein(a) levels in patients with coronary artery disease and healthy individuals.
Single-center, retrospective observational study
Enrolled 724 patients with acute coronary syndrome and 579 with chronic coronary syndrome
Included 2407 healthy individuals who underwent medical check-up
Measured lipoprotein(a) levels before percutaneous coronary intervention and during medical check-up
Median lipoprotein(a) values were 13 mg/dl in ACS, 14 mg/dl in CCS, and 10 mg/dl in normal subjects
19.1% of ACS and 26% of CCS patients had lipoprotein(a) levels >30 mg/dl
7.8% of ACS and 11.5% of CCS patients had lipoprotein(a) levels >50 mg/dl
Patients in the CCS group were more likely to use statins compared to ACS and normal subjects

Abstract

Abstract Background Lipoprotein(a) is widely known as a risk factor for atherosclerotic vascular disease (ASCVD). There are few reports on a comparison of lipoprotein(a) levels in patients with a history of coronary artery disease (CAD) and normal subjects. Purpose We aimed to compare the levels of lipoprotein(a) in patients with acute coronary syndrome (ACS), chronic coronary syndrome (CCS), and those who underwent medical check-up, in the same region and at the almost same time. Methods This was a single-center, retrospective, observational study. We enrolled 724 patients with ACS and 579 patients with CCS who were performed percutaneous coronary intervention (PCI) at Kagawa Prefectural Central Hospital between April 2019 and March 2024. The normal subjects included 2407 individuals with no history of ASCVD who had undergone medical check-up at our hospital between August 2022 and August 2023. The lipoprotein(a) level was measured before PCI in the ACS and CCS groups, and at the time of the medical check-up in the medical check-up group. Results The mean ages were 70 years in the ACS group, 72 years in the CCS group, and 56 years in the medical check-up group (p0.001). The proportions of men were 76%, 77%, and 54%, respectively (p0.001). The medical check-up group was a population with no history of cardiovascular events, and their individual backgrounds differed significantly from the ACS and CCS groups. The median values of lipoprotein(a) were 13 mg/dl in the ACS group, 14 mg/dl in the CCS group, and 10 mg/dl in the medical check-up group (P0.001). The median values for the ACS and CCS groups were similar, but the proportion of patients with high levels tended to be higher in the CCS group. The proportion of patients with lipoprotein(a) 30mg/dl was 19.1% in the ACS group and 26% in the CCS group (p0.05), and lipoprotein(a) 50mg/dl was 7.8% and 11.5% (p0.05). The CCS group had a higher rate of statin use (66.6%, 24.1% in ACS group, 14.3% in medical check-up group; p0.001). No difference in lipoprotein(a) levels between the three groups in the group with prior statin therapy, but in the group without statins, the lipoprotein(a) level was lower in the medical check-up group. There was no significant difference in lipoprotein(a) levels between the ACS and CCS groups with or without prior statin therapy. Conclusion Levels of lipoprotein(a) are lower in normal individuals than in individuals with a history of CAD.

Ask AI

Helpful

Bookmark

View Full Paper